Enovix Corporation (ENVX): what the price requires
At today's price, Enovix Corporation (ENVX) is priced for today's economics sustained for ~36.6 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-19 · Source: https://boothcheck.com/report/ENVX
Headline
| Field | Value |
|---|---|
| Ticker | ENVX |
| Company | Enovix Corporation |
| Current price | $4.96/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | revenue-multiple |
| EV / sales paid | 54.6x |
| Steady-state operating margin assumed | 7.7% |
| Must persist for | 36.6y |
The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.
Solve inputs: computed at a 11.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~4 years.
Reconcile: at the x-ray's 9.3% required return this reads ~29.6 years; the models below use their own rates.
How unusual the bet is: elevated (limited comparison data)
| Reference | Value |
|---|---|
| sustained it ~10 years at this level | 15% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 4.71x | 2 | expensive |
| Earnings | — | 0 | — |
| Relative | 12.72x | 2 | expensive |
| Growth | 1.44x | 1 | expensive |
Families that call it expensive: Asset, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.5%); the inversion above states its own rate.
Per-Model Detail (n=5)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $0.00 | — | no | Negative/zero FCF — equity value floored at $0 |
| DCF Exit Multiple | Growth | $0.00 | — | no | Negative/zero FCF or EBITDA — equity value floored at $0 |
| Relative Valuation | Relative | $0.39 | 12.72x | yes | P/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $1.11 | 4.47x | yes | Book value floor: BV/sh $1.11, ROE negative |
| Two-Stage Excess Return | Asset | $1.00 | 4.96x | yes | Book value with convergence: BV/sh $1.11, ROE converges to ke |
| Discounted Future Market Cap | Growth | $3.44 | 1.44x | yes | Rev $0.0B, growth 30% (input: historical growth; tapered), Terminal P/S: 10.5x / 15.0x / 19.5x (bear / base = today's held flat / bull, cap 15x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $0.39 | 12.72x | yes | Revenue $0.03B × sector P/S 2.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $1.1m |
| Interest coverage | -13.7x |
| Share count CAGR (dilution) | 9.1% |
| Burning cash | yes |
Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.
Bullet Takeaways
- Enovix is an early-stage story stock, not a mature business: revenue was just $7.6 million last quarter, the operating margin is deeply negative, and every earnings-based valuation method floors at zero. At $7.06 the price is a bet on commercialization that has not happened yet, against a book value near $1.11.
- The catalysts are real and dated. The company began commercial production of a silicon-anode smart-eyewear battery targeting about 50,000 units in 2026, aligned with Honor and a second OEM on a smartphone qualification framework, and reported a pipeline exceeding $130 million across drone, defense, and industrial markets.
- The two variables that decide everything are customer adoption timing and the capital markets. Enovix burned about $33 million of operating cash in the quarter and ended with $582.7 million of liquidity, while the share count has grown about 9 percent a year, so dilution funds the wait for volume.
Bull Case
Frame Enovix for what it actually is and the analysis becomes clearer: this is a speculative-stage battery-technology company priced as an option, not a mature manufacturer to be valued on current earnings. The model labels it mature, but the financials say otherwise, revenue of $7.6 million and a deeply negative operating margin, so the right lens is whether the silicon-anode technology reaches commercial scale, not what the trailing numbers show. On that lens, the recent quarter is the most encouraging in the company's history. Enovix describes itself as building lithium-ion batteries with proprietary silicon-anode architectures for smartphones, smart eyewear, defense, industrial, and emerging edge-AI applications (ENVX FY2025 10-K, accession 0001828318-26-000006), and silicon anodes promise higher energy density than conventional graphite, which is exactly what space-constrained devices like smart glasses need.
The commercialization is starting to show up in dated milestones rather than promises. First-quarter revenue rose 49 percent to $7.6 million, above the high end of guidance, on defense and industrial shipments, and non-GAAP gross margin reached 26.3 percent, a sign the early production is not deeply unprofitable per unit. The company began commercial production of its silicon-anode smart-eyewear battery, targeting about 50,000 units in 2026 and ramping in the third quarter to support a leading reference platform, with the smart-eyewear market potentially topping $1 billion by 2030. It also received a sizable pre-paid purchase order from a Silicon Valley leader in AI and immersive technologies for next-generation head-worn mixed-reality wearables, a contract structure that signals genuine customer commitment rather than a letter of intent.
The smartphone opportunity is the larger prize and it is advancing. Enovix aligned with Honor and a second smartphone OEM on a silicon-anode-specific qualification framework that reflects real-world usage, a meaningful step toward design wins in a market measured in hundreds of millions of units. The balance sheet funds the wait: $582.7 million of cash and securities gives multiple years of runway at the current burn. The discounted-future-market-cap method, the only one that credits the growth, lands near $3.44, and the margin-trajectory method near $0.43, both far below the price, which is honest about the speculation. The bull case is not that Enovix is cheap on any current metric; it is that a funded, technically differentiated battery maker with smart-eyewear production underway and smartphone qualification progressing is an option on a large market, and options on real platforms are worth paying for.
Bear Case
The variable with the most leverage on Enovix is external and almost entirely outside management's control: whether large device makers actually qualify and adopt its batteries at scale, and on what timeline. The price embeds a successful commercialization that has not yet happened. The honest read of the qualification news is sobering on timing: initial Honor field tests are expected to be small, likely only in the thousands of units, with a meaningful smartphone ramp not anticipated until 2027. Smart-eyewear volume is real but tiny, about 50,000 units in 2026. So the revenue that justifies a $7.06 price (June 27, 2026) is years away and depends on decisions by Honor, a second OEM, and the immersive-technology customer that Enovix cannot dictate. If any of them delays, re-specs, or chooses a competing chemistry, the timeline that the price assumes slips, and a pre-revenue valuation is exquisitely sensitive to timeline.
The second exposure is the capital markets, which for a cash-burning company is a macro variable as much as a company one. Enovix used about $33.1 million of operating cash in the quarter, up from $16.9 million a year earlier, and free cash flow was an outflow of $36.3 million. The $582.7 million liquidity position is substantial, but the burn is rising as the company scales manufacturing, and the path to positive cash flow runs through the same uncertain customer ramps. Crucially, the share count has grown about 9 percent a year, which means existing holders are being diluted to fund the wait. If equity markets tighten or sentiment toward unprofitable growth sours, raising the next tranche of capital becomes more expensive and more dilutive, and the stock is a battery story competing for the same risk appetite as every other speculative name.
The third issue is that there is no valuation floor to catch a disappointment. Book value per share is about $1.11, so the price is more than six times book, and every earnings-based and cash-flow method floors at zero because the business does not earn its cost of capital, with trailing ROE around negative 71 percent. The price is characterized as extreme, a bet beyond what any standard frame supports, with an implied durability horizon of 40 years. That is the model's way of saying the price is pure optionality. Analyst targets have been reset to a wide $6 to $21 range, which captures exactly this binary. Buy it and you are underwriting customer adoption on an uncertain timeline, funded by continued dilution, with essentially no downside protection if the commercialization slips.
Valuation
Enovix cannot be valued on current fundamentals, and the model says so plainly: the price is extreme, a bet beyond what any standard valuation family supports, with a current operating margin around negative 520 percent and an implied durability horizon of 40 years. This is a pre-commercialization technology company, and the only honest valuation is a probability-weighted view of whether it scales.
The X-ray reflects that. The DCF and earnings-power methods are floored at zero because free cash flow and normalized EBIT are negative. The asset methods anchor on a book value per share of about $1.11, so the simple and two-stage excess-return methods land near $1, far below the price. The relative-valuation method on sales lands at $0.39 because revenue is minimal, and it is excluded from the consensus. The two methods that credit a future ramp, the discounted-future-market-cap method at $3.44 and the margin-trajectory method at $0.43, model revenue growing 30 percent and margins ramping from deeply negative toward positive over several years, and even those land at half the price or less. Every frame says the same thing: the price is well above any value the methods can support from current operations.
The synthesis is that this is optionality pricing, and it should be sized and judged as such. The book floor near $1.11 is what the equity is worth on liquidation logic; the price near $7 is what the market pays for the chance that smart-eyewear and smartphone adoption turn the $130 million pipeline and the pre-paid mixed-reality order into a real revenue base. The deciding variables are customer qualification timelines and access to capital, not any multiple. The $582.7 million of liquidity buys time, but the 9 percent annual dilution is the cost of buying it. The analyst range of $6 to $21 is the appropriate framing: a binary where the outcome depends on commercialization that has not yet occurred.
Catalysts
The first-quarter 2026 report on May 13 was the most recent catalyst. Revenue of $7.6 million rose 49 percent and beat the high end of guidance on defense and industrial shipments, non-GAAP gross margin reached 26.3 percent, and the company ended the quarter with $582.7 million of cash and securities against operating cash burn of about $33.1 million. The market is watching the burn rate closely, since it rose year over year as manufacturing scales.
The product catalysts are specific and dated. Enovix began commercial production of its silicon-anode smart-eyewear battery, targeting about 50,000 units in 2026 with a third-quarter ramp to support a leading reference platform, and received a pre-paid purchase order from a Silicon Valley AI and immersive-technology leader for next-generation head-worn mixed-reality wearables. On smartphones, the company aligned with Honor and a second OEM on a silicon-anode qualification framework, though initial field tests are expected to be small and a meaningful ramp is not anticipated until 2027. The pipeline exceeds $130 million across drone, defense, and industrial markets, with the MX-1 drone platform launched. The swing factors to monitor are qualification milestones, the smart-eyewear production ramp, the cash burn trajectory, and any capital raise given the roughly 9 percent annual share-count growth. Analyst targets span $6 to $21, with BofA raising its target on qualification progress, reflecting how binary the outcome is.
Sources: StockTitan ENVX Q1 2026 results, Parameter cash-burn watch, Investing.com BofA target raise, Seeking Alpha smart-eyewear TAM.
Peer Cohorts (Per Segment, With Filing Citations)
Enovix (consolidated battery operations) (reported)
- ENS (ENERSYS)
- FY2025 10-K: …in or parties to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of environmental, anti-competition, employment, contract and other laws. In some of these actions and…
- FY2025 10-K: …motive power batteries produced at this facility was not sufficient, given the conversion from flooded to maintenance free batteries by customers, the existing number of competitors in the market, as well as the near term decline in demand and increased uncertainty from the pandemic. The Company plans to retain the…
- ENR (ENERGIZER HOLDINGS, INC.)
- FY2025 10-K: …performance. The Company also excludes amortization of intangibles and impairment of intangible assets from segments as these are non-cash items related to the original purchase of the intangibles and are not utilized to evaluate current segment performance. Energizer's operating model includes a combination of…
- FY2025 10-K: …item is incorporated herein by reference to Part II, Item 7, "Management's Discussion and Analysis of Financial Conditions and Results of Operations" (MD&A); and Notes 1 and 2 to our Consolidated Financial Statements. Unless the context indicates otherwise, the terms "Energizer," the "Company," "we," "us" or "our" in…
- SPB (Spectrum Brands Holdings, Inc.)
- FY2025 10-K: …initiatives such as the acquisition or divestiture of a business, related integration or separation costs, or the development and implementation of strategies to optimize or restructure the Company and its operations. Segment net sales consists of revenue generated by contracts with external customers for the sale of…
- FY2025 10-K: …"2031 Notes") (collectively, the "Tendered Notes") and redeemed the remaining outstanding principal balance of the 2026 Notes, resulting in the reduction of the principal debt balance of $1,174.4 million and recognition of a loss on early extinguishment of $2.2 million. • During the year ended September 30, 2024, the…
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.